AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06138314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
Study NCT06179407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
Study NCT06547437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: papaverine a smooth muscle relaxant
Study NCT06547437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 0.9% 100 cc
Study NCT05937841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 21
Description: AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response
Study NCT05830708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus sp. probiotic
Description: The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.
Study NCT05830708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy
Description: The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.
Study NCT05830708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
Study NCT05967598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
Study NCT05967598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
Study NCT05967598 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham cyma conchae stimulation
Description: The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1.
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1.
Study NCT05896228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).
Study NCT05121766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 (EPA+DHA)
Description: Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA.
Study NCT05121766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 Soybean Oil Placebo capsules
Study NCT05697627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) using EndeavorRx
Description: The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility Dynamic Treatment Intervention
Description: 1) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Living Intervention for Heavy Alcohol Users
Description: 1) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Linkage
Description: 1) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP/PEP at Outpatient Clinics
Description: Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP/PEP at Antenatal Clinics
Description: Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP/PEP at Community Households
Description: Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Local country standard of care protocols
Study NCT04810650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Community
Description: Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
Study NCT05473988 — intervention group
Intervention type: OTHER
Intervention: Admission to General Ward
Description: Admission to General Ward
Study NCT05473988 — intervention group
Intervention type: OTHER
Intervention: Admission to Intensive Care Unit
Description: Admission to Intensive Care Unit
Study NCT06138314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
Study NCT05473988 — intervention group
Intervention type: OTHER
Intervention: 30 Day Mortality
Description: 30 Day Mortality
Study NCT05302674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Dry
Description: 98°F (36.7°C) and 20% relative humidity environment
Study NCT06416566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Enoxaparin
Description: Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
Study NCT05485740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive multisensory rehabilitation
Description: sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
Study NCT05485740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the selected exercise program
Description: Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
Study NCT06163963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer
Description: This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
Study NCT06163963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: charcoal injection to uterus to map sentinel lymph nodes
Description: During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.
Study NCT05837338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154
Description: BXP154 will be self-administered topically following wound induction
Study NCT05837338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction
Study NCT06146257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule
Study NCT05012345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Below Elbow cast
Description: below-elbow cast ( 4 or 6 weeks )
Study NCT06495983 — intervention group
Intervention type: DEVICE
Intervention: dynamic microdialysis sampling
Description: Included patients will perform 24-hour dynamic microdialysis sampling from subcutaneous tissue fluid of the lower abdomen, applying the U-Rhythm sampler. Simutaneous measurements of blood pressure, glucose, and registration of activity level, meals and sleep pattern during microdialysis sampling may be performed. Microdialysis sampling will be performed during various conditions: during daily life activities, during saline infusion suppression testing and during dexamethasone suppression testing. Repeated sampling may be performed post treatment.
Study NCT06485024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modeling Resin
Description: it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
Study NCT06485024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modeling Resin
Description: it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
Study NCT05608421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1MoreStep
Description: Cognitive behavioral intervention to reduce HIV and IPV stigma.
Study NCT05608421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1MoreStepControl
Description: This is an equal attention control group.
Study NCT05372718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant non-immunogenic staphylokinase (Fortelyzin®)
Description: lyophilisate for preparation a solution
Study NCT05372718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical methods of treatment
Description: Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
Study NCT05961553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling session
Description: The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
Study NCT05961553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Reabilitation
Description: The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
Study NCT05961553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Reabilitation
Description: The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
Study NCT05379179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Study NCT05379179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Study NCT04446637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
Description: Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
Study NCT04446637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
Description: Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
Study NCT05421949 — intervention group
Intervention type: OTHER
Intervention: Exercise group
Description: Incremental Shuttle Walking Test
Study NCT05083351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MightySat
Description: Noninvasive pulse oximeter
Study NCT05604846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ProPrems
Description: The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
Study NCT05604846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProPrems
Description: The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
Study NCT06275451 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview on emotional regulation and administration of questionnaires lasting approximately 2 hours.
Study NCT05544240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-101
Description: SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Study NCT05892224 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Obese patients of different subtypes were all expected to undergo bariatric surgery
Study NCT06251167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (LWIs)
Description: Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. The LWIs will be constructed via 3D printing using a material of uniform density made to the length of the participant's feet, and will incorporate a 6 degree wedge along the lateral edge.